Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Recursion Pharmaceuticals, Inc., Sarepta Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Recursion Pharmaceuticals, Inc., Sarepta Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Recursion Pharmaceuticals, Inc., Sarepta Therapeutics and Inc.

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children’s Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Latest Biotechnology and Recursion Pharmaceuticals, Inc., Sarepta Therapeutics, Inc. Stock News

As of July 31, 2026, Recursion Pharmaceuticals, Inc. had a $1.6 billion market capitalization, compared to the Biotechnology median of $252.6 million. Recursion Pharmaceuticals, Inc.’s stock is down 26.7% in 2026, up 1.4% in the previous five trading days and down 48.37% in the past year.

Currently, Recursion Pharmaceuticals, Inc. does not have a price-earnings ratio. Recursion Pharmaceuticals, Inc.’s trailing 12-month revenue is $66.4 million with a -842.9% net profit margin. Year-over-year quarterly sales growth most recently was -55.8%. Analysts expect adjusted earnings to reach $-0.918 per share for the current fiscal year. Recursion Pharmaceuticals, Inc. does not currently pay a dividend.

As of July 31, 2026, Sarepta Therapeutics, Inc. had a $1.6 billion market cap, putting it in the 51st percentile of all stocks. Sarepta Therapeutics, Inc.’s stock is down 30.9% in 2026, down 5.2% in the previous five trading days and down 11.28% in the past year.

Currently, Sarepta Therapeutics, Inc.’s price-earnings ratio is 23.3. Sarepta Therapeutics, Inc.’s trailing 12-month revenue is $2.2 billion with a 3.0% net profit margin. Year-over-year quarterly sales growth most recently was -1.9%. Analysts expect adjusted earnings to reach $4.786 per share for the current fiscal year. Sarepta Therapeutics, Inc. does not currently pay a dividend.

How We Compare Recursion Pharmaceuticals, Inc., Sarepta Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Recursion Pharmaceuticals, Inc., Sarepta Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Recursion Pharmaceuticals, Inc., Sarepta Therapeutics and Inc. Growth Grades

Company	Ticker	Growth
Recursion Pharmaceuticals, Inc.	RXRX	D
Sarepta Therapeutics, Inc.	SRPT	D

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Recursion Pharmaceuticals, Inc. has a Growth Score of 29, which is Weak. Sarepta Therapeutics, Inc. has a Growth Score of 29, which is Weak.

The Growth Stock Winner: No Clear Winner

Neither Recursion Pharmaceuticals, Inc., Sarepta Therapeutics or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Recursion Pharmaceuticals, Inc., Sarepta Therapeutics or Inc. is the better investment when it comes to sustainable growth.

Recursion Pharmaceuticals, Inc., Sarepta Therapeutics and Inc.’s Quality Grades

Company	Ticker	Quality
Recursion Pharmaceuticals, Inc.	RXRX	D
Sarepta Therapeutics, Inc.	SRPT	C

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Recursion Pharmaceuticals, Inc. has a Quality Score of 26, which is Weak. Sarepta Therapeutics, Inc. has a Quality Score of 53, which is Average.

The Quality Stock Winner: No Clear Winner

Neither Recursion Pharmaceuticals, Inc., Sarepta Therapeutics or Inc. has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Recursion Pharmaceuticals, Inc., Sarepta Therapeutics or Inc. is the better investment when it comes to quality.

Recursion Pharmaceuticals, Inc., Sarepta Therapeutics and Inc.’s Momentum Grades

Company	Ticker	Momentum
Recursion Pharmaceuticals, Inc.	RXRX	F
Sarepta Therapeutics, Inc.	SRPT	D

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Recursion Pharmaceuticals, Inc. has a Momentum Score of 14, which is Very Weak. Sarepta Therapeutics, Inc. has a Momentum Score of 25, which is Weak.

The Momentum Stock Winner: No Clear Winner

Neither Recursion Pharmaceuticals, Inc., Sarepta Therapeutics or Inc. has a strong enough Momentum Grade to be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Recursion Pharmaceuticals, Inc., Sarepta Therapeutics or Inc. is the better investment when it comes to momentum.

Other Recursion Pharmaceuticals, Inc., Sarepta Therapeutics and Inc. Grades

In addition to Growth, Momentum and Quality, A+ Investor also provides grades for Value and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Recursion Pharmaceuticals, Inc., Sarepta Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Recursion Pharmaceuticals, Inc., Sarepta Therapeutics or Inc. Stock?

Overall, Recursion Pharmaceuticals, Inc. stock has a Growth Score of 29, Momentum Score of 14 and Quality Score of 26.

Sarepta Therapeutics, Inc. stock has a Growth Score of 29, Momentum Score of 25 and Quality Score of 53.

Comparing Recursion Pharmaceuticals, Inc., Sarepta Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.